Effect of an intensive lifestyle intervention on the structural and functional substrate for atrial fibrillation in people with metabolic syndrome

Xavier Rossello[1,2]#, Raúl Ramallal[3]#, Dora Romaguera[1,4] *, Ángel M. Alonso-Gómez,[4,5] Álvaro Alonso[6], Lucas Tojal-Sierra,[4,5] Carlos Fernández-Palomeque,[1,2] Miguel Ángel Martínez-González,[4,7,8] María Garrido-Uriarte,[5] Luis López,[9] Agnes Díaz,[10] Olatz Zaldua-Irastorza,[5] Amit J. Shah[6,11], Jordi Salas-Salvadó,[4,12] Montserrat Fitó,[4,13] Estefanía Toledo[4,7].

[1] *Health Research Institute of the Balearic Islands (IdISBa), Palma, Spain*

[2] *Cardiology Department, Hospital Universitari Son Espases, Palma, Spain*

[3] *Department of Cardiology, University Hospital of Navarra, Servicio Navarro de Salud Osasunbidea, IDISNA, Pamplona, Spain*

[4] *CIBER Physiopathology of Obesity and Nutrition (CIBEROBN), Carlos III Health Institute (ISCIII), Madrid, Spain*

[5] *Bioaraba Health Research Institute, Osakidetza Basque Health Service, Araba University Hospital, University of the Basque Country UPV/EHU, Vitoria-Gasteiz, Spain*

[6] *Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA*

[7] Department of Preventive Medicine and Public Health, University of Navarra, IdiSNA, Pamplona, Spain

[8] Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, United States

[9] *Cardiology Service, Hospital de Manacor, Manacor, Spain*

[10] *Cardiology Service, Clinica Universidad de Navarra, Pamplona, Spain*

[11] *Department of Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta, GA, USA*

[12] *Human Nutrition Unit, Department of Biochemistry and Biotechnology, Rovira i Virigili University, Reus, Spain*

[13] *Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain*

Total word count: 3846 (excluding structured abstract, tables, figures, references and online-only supporting information)

*Corresponding author:

Dora Romaguera, Health Research Institute of the Balearic Islands (IdISBa), Hospital Universitari Son Espases. Carretera de Valldemossa, 79, 07120 Palma, Illes Balears, Spain. **Email: mariaadoracion.romaguera@ssib.es**

#Shared first authorship

ABSTRACT

Aims. To evaluate the effect of an intensive lifestyle intervention (ILI) on the underlying structural and functional cardiac substrate of atrial fibrillation (AF) in overweight or obese people with metabolic syndrome (MetS).

Methods. Participants of the PREDIMED-PLUS trial (n=6874) were randomised 1:1 to an ILI program based on an energy-reduced Mediterranean Diet, increased physical activity, and cognitive-behavioural weight management, or to a control intervention of low-intensity dietary advice. Transthoracic echocardiography (TTE) was evaluated in a subsample of 534 participants by a core lab at baseline, 3-year and 5-year follow-up. Mixed models were used to evaluate the effect of the ILI on left atrial (LA) structure and function.

Results. In the subsample (n=534), mean age at inclusion was 66 years (SD 5 years), and 40% of the participants were women. Over the 5-year period, both groups experienced worsening of LA structure and function, with increases in LA volumes and stiffness index and decreases in LA longitudinal strain, LA function index and LA emptying fraction over time. Changes in the ILI and control group were not significantly different for any of the primary outcomes (LA emptying fraction: -0.95% (95%CI -0.93, -0.98) in control group, -0.97% (95%CI -0.94, -1.00) in ILI group, $p_{between\ groups}$=0.80; LA longitudinal strain: 0.82% (95%CI 0.79, 0.85) in control group, 0.85% (95%CI 0.82, 0.89) in ILI group, $p_{between\ groups}$=0.24) or any of the secondary outcomes.

Conclusions. In overweight or obese people with MetS, an ILI had no impact on the underlying structural and functional cardiac substrate of AF, as assessed by transthoracic echocardiography.

KEYWORDS

intensive lifestyle intervention, atrial fibrillation, obesity, metabolic syndrome, Mediterranean diet

INTRODUCTION

Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia, and a risk factor for stroke, heart failure, dementia, and mortality. [1,2] AF is a progressive disease, with many patients advancing over time from subclinical states (changes in the atrial substrate) to clinical forms of the arrhythmia (paroxysmal, persistent and then permanent AF).[3] Before AF occurs, several adaptive functional and structural changes take place in the left atrium (LA).[3] These changes, as well as the likelihood to progress to AF, are mostly determined by the presence of concomitant risk factors.

Both metabolic syndrome (MetS) and increased body weight are major risk factors for AF development and progression, since they have an impact on cardiovascular hemodynamics as well as on cardiac function and structure.[4–6] Several studies have shown that lifestyle changes controlling such risk factors may play a role in AF prevention.[3,7] In this line, a meta-analysis of randomised and observational studies reported that weight loss in obese individuals was associated with favourable hemodynamic effects,[8] whereas a post-hoc analysis of the Prevención con Dieta Mediterránea (PREDIMED) trial showed a reduced risk of newly-diagnosed AF in those allocated to a nutritional intervention fostering the adherence to a Mediterranean Diet (MedDiet) enriched with extra-virgin olive oil in comparison with those who were allocated to the advice on a low-fat diet.[7] Although the underlying pathophysiology mediating this effect is unknown, it seems plausible that lifestyle interventions can favourably reverse the remodelled cardiac substrate or slow down its remodelling in people with increased weight and MetS, and therefore reduce their natural progression to AF.[9]

In this ancillary study of the PREDIMED-Plus trial, we aimed to evaluate the effect of an intensive lifestyle intervention (ILI) based on an energy-reduced MedDiet, increased physical activity, and cognitive-behavioural weight management on the underlying structural and functional cardiac substrate of AF in overweight or obese people with MetS.

METHODS

Study population

Participants were recruited for the PREvención con DIeta MEDiterranea-Plus (PREDIMED-Plus; ISRCTN89898870), which is a multicentre, randomised trial for the primary prevention of cardiovascular disease (CVD) in overweight/obese individuals with MetS. Between 2013 and 2016, 3,574 men (aged 55-75 years) and 3,300 women (aged 60-75 years) with a body mass index ≥27 and <40 kg/m^2 meeting ≥3 criteria for the MetS were recruited from 23 centres in Spain. MetS was defined according to International Diabetes Federation, American Heart Association, and National Heart, Lung, and Blood Institute criteria.[10] Participants were randomised 1:1 to an intensive lifestyle intervention (ILI) program based on an energy-reduced MedDiet, increased physical activity, and cognitive-behavioural weight management, or to a control intervention of low-intensity dietary advice on the MedDiet during at least 6 years. Primary endpoints of the trial are (1) a composite of non-fatal myocardial infarction, non-fatal stroke, or CVD death; and (2) weight loss and long-term weight-loss maintenance.

In this ancillary study of the PREDIMED-Plus trial, a sub-sample of 566 participants from 3 centres (University of Navarra-Preventiva, Hospital Universitario Araba, and Hospital Universitari Son Espases) were invited to evaluate the effect of the intervention on the underlying atrial substrate of AF. In this substudy, patients prospectively underwent transthoracic echocardiography (TTE) at baseline, 3-year and 5-year follow-up according to a uniform protocol, which has been detailed previously.[11] After excluding participants with missing values in all TTE measures (n=20), and participants with baseline AF (n=12), 534 participants remained in the study population (**Figure 1**).

Images were then transferred to a core lab for their assessment.[11] The rationale and design of the corelab Palma Echo Platform (PEP) has been published elsewhere.[11].

Study interventions

Participants randomised to the intervention group were instructed to follow an energy-reduced MedDiet, accompanied by physical activity promotion and behavioural support, with the purpose of accomplishing specific weight loss objectives.[12] Trained dietitians conducted a group session, an individual motivational interview, and a phone call each month during the first year. Considering baseline customary levels of physical activity of each participant in the intervention group, a reduction of approximately 30% of estimated energy requirements (a reduction of roughly 600 kcal/d) was recommended. Participants in the control group attended 2 educational sessions per year on the traditional MedDiet without caloric restriction, all contents previously used in PREDIMED trial,[13] and general lifestyle recommendations according to standard of care. Participants were also encouraged to progressively increase aerobic PA to ≥ 150 min/week of moderate-to-vigorous PA, with the final goal of walking ≥ 45 min/day or equivalent, and doing specific exercises to improve strength, balance, and flexibility. Compliance with PA recommendations was evaluated using validated questionnaires. Both groups of participants were supplied for free with extra-virgin olive oil (1 L/month) and all participants were encouraged to consume 500 g/month of mixed nuts.

Study outcomes

TTE tests longitudinally and systematically assessed structural and functional features of the left atrium and other cardiac chambers. Data acquisition was performed according to the standards of the European Association of Echocardiography and the American Society of Echocardiography (ASE). [14] TTEs were performed at each site at baseline, 3-year and 5-year follow-up following a standardized protocol.[11] Images were obtained at each centre by cardiologists with expertise in cardiac imaging, but they were assessed in a blind fashion by two independent expert cardiologists (core lab evaluators) not involved in obtaining the images. Each cardiologist was responsible for assessing a set of outcomes, so that each

echocardiographic measure was assessed by one single cardiologist through the entire follow-up. The main study outcomes were LA emptying fraction, LA longitudinal strain, indexed and maximum LA volume, LA conduit and pump strain, LA stiffness index, and LA function index.[15,16]

Other variables

In addition to the imaging data, some clinical information was collected, such as age, sex, cardiovascular risk factors and medical history at baseline. Anthropometric evaluations (weight, height, waist circumference) were measured according to the PREDIMED-Plus protocol. BMI was calculated as weight (kg) divided by the square of height (m^2).

Statistical analysis

This statistical analyses had two separate aims. The primary aim was to assess the effect of the ILI on the structural and functional cardiac substrate of AF, using TTEs tests performed at baseline, 3-year and 5-year follow-up. There were two primary outcomes: left atrial emptying fraction, and left atrial peak systolic longitudinal strain. Additionally, there were six secondary outcomes: indexed and maximum left atrial volume, left atrial conduit and pump strain, left atrial stiffness index, and left atrial function index.[16]

The secondary aim was to estimate the association between changes in the 3 components of the ILI (adherence to the energy-reduced MedDiet, physical activity, and weight) and changes in echocardiographic measures at 3-year and 5-year follow-up. According to the PREDIMED-Plus protocol, a clinically relevant weight loss was defined as a reduction in baseline body weight of over 8%, and a reduction in waist circumference of over 5%. For adherence to energy-reduced MedDiet, any improvement in the p17 questionnaire was defined as a change.

For physical activity, achieving ≥150 min/week of moderate-to-vigorous exercise was defined as clinically meaningful. These changes were assessed over the 6 first months of follow-up.

Baseline characteristics were summarized as frequencies with percentages, or means with standard deviation (SD) and presented by study arm. We used mixed linear models to estimate differences in changes in LA measures from baseline to year 3 and to year 5 according to the intervention group. Time was modelled with 2 degrees of freedom (accounting for between-group differences in changes between year 3 and baseline and between year 5 and baseline. All models were adjusted for recruitment centre. We fitted a 2-level mixed linear model with random intercepts at cluster family and participant level. In an additional analysis, to address the relative changes in LA measurements over follow-up, we used linear mixed models with log-transformed LA measurements to assess the changes over time according to intervention group. Afterwards, estimates were back-transformed for an easier interpretation. As sensitivity analyses, we repeated the main analyses with multiple imputation methods using an iterative Markov chain Monte Carlo method (STATA "mi" command). We generated 20 imputations for each missing measurement. Imputed missing values were used for follow-up data but not for baseline data. Missing values for each outcome at baseline and follow-up are reported in **Supplementary Table 1**. To mitigate the potential impact of poor image quality, an additional analysis was conducted excluding participants withs suboptimal echocardiographic windows. All analyses were conducted on an intention-to-treat basis.

To estimate the association of changes in the 3 components of the intervention (weight, adherence to the energy-restricted MedDiet, and physical activity) with changes in echocardiographic measures, a separate model was used to evaluate the impact of each individual component on LA longitudinal strain. In these models, the independent variables were the change (difference) between baseline and the 6-month post-randomisation visit in each one of the intervention components defined using the 17-item energy-restricted MedDiet questionnaire, weight in kilograms, and waist circumference based on the goals set to be

achieved after 6 months in the trial protocol for physical activity. For these analyses we used 2-level mixed linear models with random intercepts at cluster family and participant level adjusted for recruitment centre, intervention group, age, sex, prevalent diabetes, use of blood pressure lowering drugs (9 different drug families), and baseline systolic blood pressure.

All analyses were conducted using Stata version 16.1 (College Station, Texas, USA). A P-value of 0.05 was considered statistically significant. GraphPad Prism version 6.00 (GraphPad Software, La Jolla, California, USA) was used to produce the figures.

RESULTS

Baseline data

The number of patients included in the analysis is summarised in the flow chart shown in **Figure 1**. Baseline characteristics of the study participants according to their randomized group are presented in **Table 1**. Mean age at inclusion was 65 years (SD 5 years), and 40% of the participants were women. Given the inclusion criteria, prevalence of cardiovascular risk factors was high in both groups. At baseline, there were no substantial differences between groups regarding adherence to the MedDiet and total energy intake, though a higher physical activity amount was observed in the control as compared to the intervention arm. Regarding TTE baseline data, there were no major differences between groups (**Table 1**).

Treatment effect on primary and secondary outcomes

Compared with the control group, the intervention group did not show a significant improvement in the primary outcomes (LA emptying fraction and LA longitudinal strain) over the 5-year period (**Figure 2**). Compared with baseline values, LA emptying fraction was lower at the end of follow-up for both groups (58.4% at baseline vs 56.4% at year 5 for the control arm, p=0.002; and 59.4% at baseline vs 57.7% at year 5 for the intervention arm, p=0.002), but not different between them ($p_{between\ groups}$=0.80). Regarding LA longitudinal strain, there was a steady

decline over time in both groups (27.5% at baseline vs 23.0% at year 5 for the control arm, p<0.001; and 27.6% at baseline vs 23.8% at year 5 for the intervention arm, p<0.001), but similarly there was no difference between groups ($p_{between\ groups}$=0.24).

The lack of treatment effect of the intervention was also observed across all the secondary outcomes (**Figure 3**): indexed LA volume ($p_{between\ groups}$=0.72), maximum LA volume ($p_{between\ groups}$=0.72), LA conduit strain ($p_{between\ groups}$=0.12), LA pump strain ($p_{between\ groups}$=0.31), LA stiffness index ($p_{between\ groups}$=0.66), and LA function index ($p_{between\ groups}$=0.99). For all endpoints, changes in endpoints followed a consistent trend in the control and the intervention group: indexed LA volume, maximum LA volume, and LA stiffness index increased over time, whereas LA conduit strain, LA pump strain, and LA function index decreased. Relative effects of the intervention on LA structural and functional echo parameters are shown as ratios of geometric means in **Table 2**, without evidence of a statistically significant effect of the intervention on any of the echocardiographic outcomes.

To evaluate the impact of missing values, the main analyses on primary and secondary outcomes were evaluated using a multiple imputation technique with 20 datasets (Supplementary **Table 2**). The findings for all outcomes were consistent to those yielded by the complete-case analysis.

To assess the influence of participants with suboptimal echocardiographic windows on the effects of ILI on primary outcomes, an additional analysis was conducted. The exclusion of these participants did not yield significant changes in the overall findings (Supplementary **Table 3**).

Association between individual components of the intervention and LA echo parameters

The association of changes in the 3 components of the intervention (adherence to the energy-restricted MedDiet, physical activity, and weight) with changes in echocardiographic measures was evaluated in all participants (**Figure 4**).

There were no significant differences in LA longitudinal strain over 5-year follow-up between those reducing and those not reducing >8% their weight loss (baseline vs. 5-year values for those not reducing weight loss were 27.6% vs 23.4%, whereas they were 27.3% vs 23.5% for those losing >8% weight; $p_{between\ groups}$=0.68). There was a consistent decline in LA longitudinal strain over time in both groups (**Figure 4, panel A**). In contrast, a borderline significant difference was observed when the change in waist circumference was evaluated ($p_{between\ groups}$=0.049), though this difference was concentrated in the 3-year follow-up (**Figure 4, panel C**).

There were no significant differences in LA longitudinal strain over 5-year follow-up between those who improved and those who did not improve the adherence to the energy reduced MedDiet (baseline vs. 5-year values for those not improving adherence were 25.7% vs 22.7%, whereas they were 28.1% vs 23.6% for those improving adherence to MedDiet; $p_{between\ groups}$=0.16). There was a consistent decline in LA longitudinal strain in both groups between baseline and year 3, whilst in year 5 those not improving adherence did not have as lower values of LA longitudinal strain as those improving adherence (**Figure 4, panel E**).

Regarding physical activity, there were no significant differences in LA longitudinal strain over 5-year follow-up between those who reached and those who did not reach the goal of ≥150 min/week of moderate-to-vigorous exercises (baseline vs. 5-year values for those not reaching goal were 27.2% vs 23.3%, whereas they were 27.7% vs 23.4% for those reaching that level of physical activity; $p_{between\ groups}$=0.54; (**Figure 4, panel G**).

The association between individual components of the intervention and LA emptying fraction was consistent with those observed for LA longitudinal strain (**Figure 4, panel B, D, F, H**).

DISCUSSION

In this nested randomised clinical trial, conducted in overweight or obese people with MetS, an ILI program based on an energy-reduced MedDiet, increased physical activity, and cognitive-behavioural weight management did not show a significant impact on the structural and functional cardiac substrate of AF compared a control intervention of low-intensity dietary advice on the MedDiet. There were significant changes in all echocardiographic endpoints (LA emptying fraction, LA peak systolic longitudinal strain, indexed and maximum LA volume, LA conduit and pump strain, LA stiffness index, and LA function index) in both arms, though these changes were similar by arm. There were no significant differences in LA longitudinal strain and LA emptying EF change by intensity of compliance with the intervention (weight loss, improvement in adherence to MedDiet, and physical activity). Compared to those with less waist circumference reduction, LA longitudinal strain decreased slower in those with the highest waist circumference reduction at year 3, although this was not observed at year 5.

People with MetS and increased body weight are at high risk for AF development and progression, since these conditions have an effect on cardiovascular hemodynamics (e.g., hypertension), as well as a consequent long-term impact on cardiac function and structure.[4,5] Some changes in LA, such as a greater increase in LA volumes and decrease in LA function, have been considered a surrogate outcome for developing AF.[9] Our findings do not support that an ILI plays a role in preventing LA changes, though these new results need to be put in context. Previous randomised and observational studies summarised in a meta-analysis showed that weight loss in obese individuals was associated with favorable hemodynamic effects,[8] which can be considered the preliminary step before changes in LA take place. A post-hoc analysis of

the PREDIMED trial showed that an intervention promoting adherence to the MedDiet enriched with extra-virgin olive oil can reduce by 40% the risk of newly-diagnosed AF compared with a control intervention promoting a low-fat diet. Our data do not contradict the findings yielded by these studies, since we do not report neither the hemodynamic changes nor the incidence of AF over time. However, our results do not support that our intervention, an ILI program based on an energy-reduced MedDiet, increased physical activity, and cognitive-behavioural weight management, have an impact on the changes that happen on LA over time in overweight or obese people with MetS.

Several reasons might explain the lack of treatment effect provided by an ILI. Given that the control intervention was a low-intensity dietary advice on the MedDiet, it is reasonable to think that the "active comparator" might have had already an impact on LA changes in the control group.[8] It might also happen that the ILI is not having an impact on LA outcomes, unlike other lifestyle interventions might have. This is supported by the data provided for the attainment of each individual component of the intervention. Given that those patients with higher degree of compliance with clinically relevant goals (weight loss, MedDiet adherence, physical activity) did not have different outcomes than those with a lower degree of compliance, it seems that none of the individual interventions is driving any treatment effect. Another explanation for the lack of treatment effect might be the selection of echocardiographic endpoints. Perhaps LA changes are not good surrogates to be tested. The use of surrogate endpoints requires prior validation,[17] since they should be consistently measurable and sensitive to the intervention, they should predict events and moreover, their response to an intervention should predict the response to the intervention in a RCT using clinical outcomes.[18] We tested an ILI under the hypothesis that smaller changes in LA will result in a reduced number of AF episodes in the long-term. This paradigm assumes that the risk for AF is greatly dependent on the degree of LA impairment. Eventually, LA changes could be good clinical markers, but poor surrogate endpoints. In the MESA study, a cohort of people free of CVD at baseline, a greater

increase in LA volumes and decrease in LA function was associated with incident AF, whereas a change in LA emptying fraction improved model discrimination and reclassification of AF risk.[9] Finally, intervention effects on lifestyle might have attenuated over time, suggesting that sustained effects need a different strategy to change behaviours in the long term. There are several examples of a transient favourable change after a lifestyle intervention that tend to dilute over time, such as those observed in the recently published TANSNIP-PESA (Trans-Atlantic Network to study Stepwise Non-invasive Imaging as a tool for CVD Prognosis and prevention) study.[19] In addition, the COVID-19 pandemic might have had an impact of the trial conduct, though no major effects have been observed in previous reports.[20] Our intervention might influence some biomarkers (also surrogates for AF), but might have little influence in echo parameters should they be already altered before enrolment in the trial (e.g., long-standing obesity).[21] There were no significant differences in LA longitudinal strain and LA emptying fraction according to changes in each individual component of the intervention, which was consistent with the lack of treatment effect on the primary outcomes.

Both AF and metabolic syndrome (MetS) are becoming a global public health issue due to the aging of the population and the increasing levels of obesity and physical inactivity among adults in many countries.[22,23] Although we failed to show efficacy on echocardiographic outcomes in the comparison between ILI and low-intensity dietary advice on the MedDiet, it seems plausible that other lifestyle interventions can favourably reverse the remodelled cardiac substrate of people with increased weight and MetS, and therefore reduce their natural progression to AF.[9] In the REVERSE-AF (PREVEntion and regReSsive Effect of weight-loss and risk factor modification on Atrial Fibrillation) study,[3] weight loss and risk factor management reversed the type and natural progression of AF in patients with already some form of AF. Similarly, aggressive risk factor reduction improved the long-term success of AF ablation, underscoring the importance of therapy directed at the primary promoters of the AF substrate to facilitate rhythm control strategies.[24]

The use of echocardiography in this setting deserves special attention. The atrium has been historically evaluated in its morphological dimension (e.g., atrial volume). In our study, we evaluated novel parameters, such as LA strain and emptying fraction.[25,26] Unlike traditional parameters based on blood flow during atrial contraction such as the peak A wave velocity or the A wave velocity time integral, LA strain represents a reliable direct measure of atrial function.[25,26]

Strengths and limitations of this study

Strengths of this trial include an adequate sample size to fairly answer the main hypothesis, the randomised design, reducing the threat of confounding, the prolonged intervention and follow-up periods for the study of lifestyle-change maintenance, the excellent retention during follow-up, and the objective measurement of the echo outcomes. Nesting this study within the PREDIMED-PLUS trial provides a perfect opportunity for further comprehensive assessments of the association between lifestyle changes and myocardial derangements. Nevertheless, several limitations should be considered. This is a nationwide trial of highly selected patients (increased weight with MetS enriched with at least 3 factors), and therefore the generalisation of the findings should be taken cautiously.[27] Due to the type of intervention, neither participants nor investigators were blinded to the allocation arm, though we were masked for the statistical analysis and all study outcomes relied on objective parameters not subject to self-report bias. The level of statistical significance has not been adjusted for the number of comparisons[28]. It should be acknowledged that an optimal TTE acquisition is particularly challenging in a population with a high body mass index and MetS. It is also challenging to obtain standard values in a hypothetical reference population, given the difference between commercial software's measuring LA strain. Other techniques, such as cardiac magnetic resonance, might be useful to complement echo measures in future studies.

CONCLUSIONS

Using randomised data from overweight or obese people with MetS, we observed that an ILI program based on an energy-reduced MedDiet, increased physical activity, and cognitive-behavioural weight management did not have an effect on none of the primary (LA emptying fraction, and LA peak systolic longitudinal strain) or secondary (indexed and maximum LA volume, LA conduit and pump strain, LA stiffness index, and LA function index) echocardiographic endpoints. Our findings suggest that there are changes over time in these parameters, but that an ILI has no impact on them. Hence, an ILI had no impact on the underlying structural and functional cardiac substrate of AF in overweight or obese people with MetS. Similarly, those achieving higher goals in terms of weight loss, adherence to MedDiet, or physical activity, showed no difference in LA longitudinal strain compared to those below clinically relevant changes.

REFERENCES

1. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the Europe. *Eur Heart J* 2021;**42**:373–498.

2. Rozen G, Hosseini SM, Kaadan MI, Biton Y, Heist EK, Vangel M, etal. Emergency Department Visits for Atrial Fibrillation in the United States: Trends in Admission Rates and Economic Burden From 2007 to 2014. *J Am Heart Assoc* 2018;**7**: e009024.

3. Middeldorp ME, Pathak RK, Meredith M, Mehta AB, Elliott AD, Mahajan R, Twomey D, Gallagher C, Hendriks JML, Linz D, McEvoy RD, Abhayaratna WP, Kalman JM, Lau DH, Sanders P. PREVEntion and regReSsive Effect of weight-loss and risk factor modification on Atrial Fibrillation: the REVERSE-AF study. *Europace*; 2018;**20**:1929–1935.

4. Lavie CJ, Pandey A, Lau DH, Alpert MA, Sanders P. Obesity and Atrial Fibrillation Prevalence, Pathogenesis, and Prognosis: Effects of Weight Loss and Exercise. *J Am Coll Cardiol* 2017;**70**:2022–2035.

5. Feng T, Vegard M, Strand LB, Laugsand LE, Mørkedal B, Aune D, et al. Weight and weight change and risk of atrial fibrillation: the HUNT study. *Eur Heart J* 2019;**40**:2859–2866.

6. Raposeiras-Roubín S, Abu-Assi E, Lizancos Castro A, Barreiro Pardal C, Melendo Viu M, Cespón Fernández M, et al. Nutrition status, obesity and outcomes in patients with atrial fibrillation. *Rev Esp Cardiol (Engl Ed)* 2022;**75**:825–832.

7. Martínez-González MÁ, Toledo E, Arós F, Fiol M, Corella D, Salas-Salvadó J, et al. Extravirgin olive oil consumption reduces risk of atrial fibrillation: the PREDIMED (Prevención con Dieta Mediterránea) trial. *Circulation* 2014;**130**:18–26.

8. Reddy YN V, Anantha-Narayanan M, Obokata M, Koepp KE, Erwin P, Carter RE, et al. Hemodynamic Effects of Weight Loss in Obesity: A Systematic Review and Meta-Analysis. *JACC Heart Fail* 2019;**7**:678–687.

9. Lim DJ, Ambale-Ventakesh B, Ostovaneh MR, Zghaib T, Ashikaga H, Wu C, et al. Change in left atrial function predicts incident atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis.*Eur Heart J Cardiovasc Imaging* 2019;**20**:979–987.

10. Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA,et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation* 2009;**120**:1640–1645.

11. López L, Rossello X, Romaguera D, Alonso-Gómez ÁM, Toledo E, Fortuny E, et al. The Palma Echo Platform: Rationale and Design of an Echocardiography Core Lab. *Front Cardiovasc Med* 2022;**9**:909347.

12. Sayón-Orea C, Razquin C, Bulló M, Corella D, Fitó M, Romaguera D, et al. Effect of a Nutritional and Behavioral Intervention on Energy-Reduced Mediterranean Diet Adherence Among Patients With Metabolic Syndrome: Interim Analysis of the PREDIMED-Plus Randomized Clinical Trial. *JAMA* 2019;**322**:1486–1499.

13. Estruch R, Ros E, Salas-Salvadó J, Covas M-I, Corella D, Arós F, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. *N Engl J Med* 2018;**378**:e34.

14. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an

update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging* 2015;**16**:233–270.

15. Mitchell C, Rahko PS, Blauwet LA, Canaday B, Finstuen JA, Foster MC,et al. Guidelines for Performing a Comprehensive Transthoracic Echocardiographic Examination in Adults: Recommendations from the American Society of Echocardiography. *J Am Soc Echocardiogr* 2019;**32**:1–64.

16. Florescu DR, Badano LP, Tomaselli M, Torlasco C, Târtea GC, Bălșeanu TA, et al. Automated left atrial volume measurement by two-dimensional speckle-tracking echocardiography: feasibility, accuracy, and reproducibility. *Eur Heart J Cardiovasc Imaging* 2021;**23**:85–94.

17. Weintraub WS, Lüscher TF, Pocock S. The perils of surrogate endpoints. *Eur Heart J* 2015;**36**:2212–2218.

18. Domanski M, Pocock S, Bernaud C, Borer J, Geller N, Revkin J, et al. Surrogate endpoints in randomized cardiovascular clinical trials. *Fundam Clin Pharmacol* 2011;**25**:411–413.

19. Garcia-Lunar I, Ploeg HP van der, Fernández Alvira JM, Nassau F van, Castellano Vázquez JM, et al. Effects of a comprehensive lifestyle intervention on cardiovascular health: the TANSNIP-PESA trial. *Eur Heart J* 2022;**43**:3732–3745.

20. Paz-Graniel I, Fitó M, Ros E, Buil-Cosiales P, Corella D, Babio N, et al. Impact of COVID-19 pandemic on the PREDIMED-Plus randomized clinical trial: Effects on the interventions, participants follow-up, and adiposity. *Front Nutr* 2022;**9**:1098269.

21. Wang W, Zhang MJ, Inciardi RM, Norby FL, Johansen MC, Parikh R, et al. Association of Echocardiographic Measures of Left Atrial Function and Size With Incident Dementia. *JAMA* 2022;**327**:1138–1148.

22. Lindsay RS, Howard B V. Cardiovascular risk associated with the metabolic syndrome.

Curr Diab Rep 2004;**4**:63–68.

23. Rossello X, Fuster V, Oliva B, Sanz J, Fernández Friera LA, López-Melgar B, et al. Association between body size phenotypes and subclinical atherosclerosis. *J Clin Endocrinol Metab* 2020;**105**:3734–3744.

24. Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey D, et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. *J Am Coll Cardiol* 2014;**64**:2222–2231.

25. Jasic-Szpak E, Marwick TH, Donal E, Przewlocka-Kosmala M, Huynh Q, Gozdzik A, et al. Prediction of AF in Heart Failure With Preserved Ejection Fraction: Incremental Value of Left Atrial Strain. *JACC Cardiovasc Imaging* 2021;**14**:131–144.

26. Boyd AC, Richards DAB, Marwick T, Thomas L. Atrial strain rate is a sensitive measure of alterations in atrial phasic function in healthy ageing. *Heart* 2011;**97**:1513–1519.

27. Rossello X, Massó-van Roessel A, Chioncel O, Tavazzi L, Ferrari R, Vahanian A, et al. EURObservational Research Programme: a bibliometric assessment of its scientific output. *Eur Heart J Qual Care Clin Outcomes* 2022;**8**:804-81.1

28. Pocock SJ, Rossello X, Owen R, Collier TJ, Stone GW, Rockhold FW. Primary and Secondary Outcome Reporting in Randomized Trials: JACC State-of-the-Art Review. *J Am Coll Cardiol* J Am Coll Cardiol 2021;**78**:827–839.

ACKNOWLEDGMENTS

The authors especially thank the PREDIMED-Plus participants for the enthusiastic collaboration, the PREDIMED-Plus personnel for outstanding support, and the personnel of all associated primary care centers and cardiology departments for the exceptional effort.

FUNDING

Research reported in this publication was supported by the National Heart, Lung, And Blood Institute of the National Institutes of Health under Award Numbers R01HL137338 and K24HL148521. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

This work was supported by the official Spanish Institutions for funding scientific biomedical research, CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN) and Instituto de Salud Carlos III (ISCIII), through the Fondo de Investigación para la Salud (FIS), which is co-funded by the European Regional Development Fund (six coordinated FIS projects leaded by JS-S and JVi, including the following projects: PI13/00673, PI13/00492, PI13/00272, PI13/01123, PI13/00462, PI13/00233, PI13/02184, PI13/00728, PI13/01090, PI13/01056, PI14/01722, PI14/00636, PI14/00618, PI14/00696, PI14/01206, PI14/01919, PI14/00853, PI14/01374, PI14/00972, PI14/00728, PI14/01471, PI16/00473, PI16/00662, PI16/01873, PI16/01094, PI16/00501, PI16/00533, PI16/00381, PI16/00366, PI16/01522, PI16/01120, PI17/00764, PI17/01183, PI17/00855, PI17/01347, PI17/00525, PI17/01827, PI17/00532, PI17/00215, PI17/01441, PI17/00508, PI17/01732, PI17/00926, PI19/00957, PI19/00386, PI19/00309, PI19/01032, PI19/00576, PI19/00017, PI19/01226, PI19/00781, PI19/01560, PI19/01332, PI20/01802, PI20/00138, PI20/01532, PI20/00456, PI20/00339, PI20/00557, PI20/00886, PI20/01158); the Especial Action Project entitled: Implementación y evaluación de una intervención intensiva sobre la actividad física Cohorte PREDIMED-Plus grant to JS-S; the European Research Council (Advanced Research Grant 2014–2019; agreement #340918) granted to MÁM-G.; the Recercaixa (number 2013ACUP00194) grant to JS-S; grants from the Consejería de Salud de la Junta de Andalucía (PI0458/2013, PS0358/2016, PI0137/2018); the PROMETEO/2017/017 grant from the Generalitat Valenciana; the SEMERGEN grant; None of the funding sources took part in the design, collection, analysis, interpretation of the data, or writing the report, or in the decision to submit the manuscript for publication.

CONFLICT OF INTEREST

All authors declare that they have no conflict of interests.

DATA AVAILABILITY STATEMENT

There are restrictions on the availability of data for the PREDIMED-Plus study, due to the signed consent agreements around data sharing, which only allow access to external researchers for research following the project purposes. Requestors wishing to access the PREDIMED-Plus trial data used in this study can request it to the PREDIMED-Plus trial Steering Committee: predimed_plus_scommittee@googlegroups.com.

FIGURES

Figure 1. Study flow chart

Figure 2. Treatment effect on co-primary outcomes.

Results from linear mixed models. Time was modelled with 2 degrees of freedom. All models were adjusted for recruitment centre. We fitted a 2-level mixed linear model with random intercepts at cluster family and participant level.

Figure 3. Treatment effect on secondary outcomes

Results from linear mixed models. Time was modelled with 2 degrees of freedom. All models were adjusted for recruitment centre. We fitted a 2-level mixed linear model with random intercepts at cluster family and participant level.

Figure 4. Association between individual components of the intervention and LA structural and functional parameters

Results from linear mixed models. Time was modelled with 2 degrees of freedom. All models were adjusted for recruitment centre. We fitted a 2-level mixed linear model with random intercepts at cluster family and participant level and adjusted for intervention group, age, sex, prevalent diabetes, use of blood pressure lowering drugs (9 different drug families), and baseline systolic blood pressure.

TABLES

Table 1. Baseline clinical and echocardiographic data

	Control (n=268)	Intervention (n=266)	Total in three participating sites (n=534)	Total PREDIMED Plus participants (n=6874)
Baseline clinical data				
Women, %	43	37	40	49
Age, years	66 (5)	65 (5)	65 (5)	65 (5)
Body-mass index, kg/m^2	31.9 (3.2)	32.5 (3.3)	32.2 (3.3)	32.6 (3.5)
Weight, Kg	85.7 (12.4)	88.5 (12.8)	87.1 (12.7)	86.6 (13.0)
Waist circumference	105 (8)	107 (8)	106 (8)	108 (10)
Smoking habit, % Current smoker Former smoker	7 53	11 49	9 51	12 44
Civil status, % Married Single Widowed Separated and divorced	79 6 7 7	76 5 14 6	78 6 10 6	77 5 10 8
Type 2 diabetes, %	29	28	28	31
Hypertension, %	88	88	88	84
Dyslipidemia, %	74	75	74	70
Physical activity, METs-min/d	2833 (2269)	2240 (2225)	2538 (2265)	2462 (2300)
Total energy intake, kcal/d	2467 (712)	2380 (614)	2423 (666)	2416 (633)
Adherence to the Mediterranean diet, 17-item screener	7.6 (3.0)	7.7 (2.9)	7.6 (2.9)	8.5 (2.7)
Alcohol intake, g/d	17 (21)	16 (21)	16 (21)	11 (15)
Baseline echo data				
Baseline LA emptying fraction, %	58.4 (9.4)	59.4 (9.4)	58.9 (9.4)	-
Baseline LA longitudinal strain, %	27.5 (6.6)	27.6 (6.5)	27.6 (6.5)	-
Indexed LA volume, mL/m^2	22.7 (6.7)	23.1 (7.4)	22.9 (7.0)	-
LA volume, mL	43.6 (14.0)	45.0 (14.9)	44.3 (14.5)	-
Conductile LA strain, %	-11.7 (4.7)	-12.2 (4.1)	-12.0 (4.4)	-
Contractile LA strain, %	-15.7 (4.6)	-15.6 (4.6)	15.6 (4.6)	-
LA stiffness index	0.3 (0.1)	0.4 (0.2)	0.4 (0.2)	-
LA function index	67.1 (28.8)	67.4 (29.6)	67.3 (29.2)	-

LV ejection fraction, %	65.7 (7.6)	64.8 (5.8)	65.2 (6.8)	-
LV longitudinal strain	-17.7 (2.6)	-17.7 (2.4)	-17.7 (2.5)	-

LA, left atrium

LV, left ventricle

Table 2. Relative effect of an intensive lifestyle intervention on left atrium structural and functional parameters

	Control group		ILI group		Difference ILI vs. control	
	Y3 vs baseline	Y5 vs baseline	Y3 vs baseline	Y5 vs baseline	Y3 vs baseline	Y5 vs baseline
LA emptying fraction	0.96 (0.94-0.99)	0.95 (0.93-0.98)	0.96 (0.93-0.98)	0.97 (0.94-1.00)	1.00 (0.96-1.03)	1.01 (0.97-1.05)
LA longitudinal strain	0.88 (0.85-0.92)	0.82 (0.79-0.85)	0.91 (0.88-0.95)	0.85 (0.82-0.89)	1.04 (0.98-1.09)	1.04 (0.98-1.10)
Indexed LA volume	1.07 (1.03-1.11)	1.19 (1.15-1.23)	1.09 (1.05-1.13)	1.18 (1.14-1.23)	1.02 (0.97-1.07)	0.99 (0.94-1.05)
LA maximum volume	1.07 (1.03-1.11)	1.19 (1.14-1.23)	1.07 (1.03-1.11)	1.16 (1.12-1.20)	1.00 (0.95-1.05)	0.98 (0.93-1.03)
LA conduit strain	0.88 (0.82-0.93)	0.84 (0.79-0.89)	0.91 (0.86-0.97)	0.82 (0.77-0.87)	1.04 (0.95-1.13)	0.98 (0.90-1.06)
LA pump strain	0.92 (0.87-0.97)	0.84 (0.79-0.89)	0.92 (0.87-0.97)	0.88 (0.83-0.93)	1.01 (0.93-1.09)	1.05 (0.97-1.13)
LA stiffness index	1.11 (1.05-1.17)	1.17 (1.11-1.23)	1.07 (1.02-1.13)	1.10 (1.04-1.16)	0.97 (0.90-1.04)	0.94 (0.87-1.02)
LA function index	0.89 (0.84-0.94)	0.82 (0.78-0.87)	0.88 (0.83-0.93)	0.82 (0.78-0.87)	0.99 (0.92-1.07)	1.00 (0.92-1.08)

Before performing mixed models, variables were log-transformed. Afterwards, they were back-transformed for an easier interpretation. In this table, values represent ratios of geometric means, alongside their 95% CI.

LA, left atrial

Models were adjusted for recruitment centre.

SUPPLEMENTARY TABLES

Supplementary Table 1. Participants with missing values in the baseline and follow-up ascertainment of the primary and secondary outcomes

Outcome	Baseline	Follow-up
LA emptying fraction, n	2	32
LA longitudinal strain, n	7	33
Indexed maximum LA volume	2	35
Maximum LA volume	2	32
LA conduit and pump strain	24	33
LA stiffness index	8	35
LA function index	12	35

LA, left atrial.

Supplementary Table 2. Sensitivity analyses of the effect of an intensive lifestyle intervention on left atrium structural and functional parameters using multiple imputations for missing data

	Control	Intervention	p-value (within groups)	p-value (between groups)
LA EF				
Baseline, mean (95% CI)	58.5 (57.4-59.7)	59.3 (58.2-60.5)	P_{int}=0.002 P_{con}=0.003	0.80
Year 3, mean (95% CI)	56.5 (55.2-57.7)	57.0 (55.8-58.2)		
Year 5, mean (95% CI)	56.4 (55.2-57.7)	57.6 (56.4-58.9)		
LA longitudinal strain				
Baseline, mean (95% CI)	27.6 (26.8-28.4)	27.6 (26.8-28.4)	P_{int}<0.001 P_{con}<0.001	0.24
Year 3, mean (95% CI)	24.5 (23.7-25.4)	25.6 (24.7-26.4)		
Year 5, mean (95% CI)	23.0 (22.1-23.9)	23.8 (22.9-24.6)		
Indexed LA volume				
Baseline, mean (95% CI)	22.6 (21.7-23.4)	23.1 (22.3-24.0)	P_{int}<0.001 P_{con}<0.001	0.72
Year 3, mean (95% CI)	24.1 (23.2-25.0)	25.1 (24.2-26.0)		
Year 5, mean (95% CI)	26.9 (26.0-27.9)	27.4 (26.5-28.4)		
Maximum LA volume				
Baseline, mean (95% CI)	43.4 (41.6-45.2)	45.2 (43.4-47.0)	P_{int}<0.001 P_{con}<0.001	0.75
Year 3, mean (95% CI)	46.2 (44.4-48.1)	47.9 (46.1-49.8)		
Year 5, mean (95% CI)	51.6 (49.7-53.4)	52.5 (50.6-54.3)		
LA conduit strain				
Baseline, mean (95% CI)	11.8 (11.3-12.3)	12.1 (11.6-12.7)	P_{int}<0.001 P_{con}<0.001	0.12
Year 3, mean (95% CI)	10.3 (9.7-10.8)	11.3 (10.7-11.8)		
Year 5, mean (95% CI)	10.0 (9.5-10.6)	10.1 (9.5-10.6)		
LA pump strain				
Baseline, mean (95% CI)	15.7 (15.1-16.3)	15.6 (15.0-16.2)	P_{int}<0.001 P_{con}<0.001	0.31
Year 3, mean (95% CI)	14.2 (13.6-14.8)	14.4 (13.8-15.0)		
Year 5, mean (95% CI)	13.1 (12.5-13.7)	13.7 (13.1-14.3)		
LA stiffness index				
Baseline, mean (95% CI)	0.35 (0.32-0.37)	0.36 (0.33-0.38)	P_{int}<0.001 P_{con}=0.001	0.65
Year 3, mean (95% CI)	0.40 (0.37-0.42)	0.40 (0.37-0.43)		
Year 5, mean (95% CI)	0.42 (0.39-0.45)	0.41 (0.38-0.44)		
LA function index				
Baseline, mean (95% CI)	67.5 (64.4-70.5)	67.2 (64.2-70.2)	P_{int}<0.001 P_{con}<0.001	0.96
Year 3, mean (95% CI)	59.9 (56.7-63.1)	58.9 (55.7-62.0)		
Year 5, mean (95% CI)	56.3 (53.1-59.5)	55.6 (52.4-58.9)		

LA, left atrial

All models were adjusted for recruitment centre.

Supplementary Table 3. Relative effect of an intensive lifestyle intervention on left atrium structural and functional parameters among visits with good echocardiographic quality

	Control group		ILI group		Difference ILI vs. control	
	Y3 vs baseline	Y5 vs baseline	Y3 vs baseline	Y5 vs baseline	Y3 vs baseline	Y5 vs baseline
LA emptying fraction	0.96 (0.93-0.99)	0.93 (0.91-0.96)	0.96 (0.93-0.98)	0.95 (0.93-0.98)	1.00 (0.96-1.04)	1.02 (0.98-1.06)
LA longitudinal strain	0.92 (0.88-0.96)	0.82 (0.79-0.86)	0.94 (0.90-0.97)	0.87 (0.84-0.91)	1.02 (0.96-1.08)	1.06 (1.00-1.12)
Indexed LA volume	1.06 (1.02-1.11)	1.22 (1.17-1.27)	1.07 (1.03-1.11)	1.18 (1.13-1.23)	1.01 (0.95-1.07)	0.97 (0.91-1.03)
LA maximum volume	1.06 (1.02-1.11)	1.21 (1.16-1.26)	1.04 (1.00-1.09)	1.15 (1.11-1.20)	0.98 (0.93-1.04)	0.95 (0.90-1.01)
LA conduit strain	0.90 (0.84-0.96)	0.84 (0.79-0.90)	0.93 (0.87-0.99)	0.85 (0.80-0.91)	1.03 (0.95-1.13)	1.02 (0.93-1.12)
LA pump strain	0.96 (0.91-1.02)	0.86 (0.81-0.92)	0.95 (0.90-1.01)	0.91 (0.86-0.96)	0.99 (0.91-1.08)	1.05 (0.97-1.14)
LA stiffness index	1.07 (1.01-1.14)	1.16 (1.09-1.23)	1.05 (0.99-1.11)	1.08 (1.01-1.14)	0.98 (0.90-1.07)	0.93 (0.85-1.01)
LA function index	0.91 (0.85-0.97)	0.79 (0.74-0.85)	0.91 (0.85-0.97)	0.81 (0.76-0.86)	1.00 (0.91-1.10)	1.02 (0.93-1.12)

Before performing mixed models, variables were log-transformed. Afterwards, they were back-transformed for an easier interpretation. In this table, values represent ratios of geometric means, alongside their 95% CI.

LA, left atrial

Models were adjusted for recruitment centre.